文献速递前列腺癌

前列腺癌基因组分类器与Gleason分级分组的相关性强于PI-RADS评分

Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
PubMed 文献 · Urology · 2018-12-12

本研究评估低至中危前列腺癌患者中PI-RADSv2评分、Decipher评分与活检组织学分级之间的关联。

要点

  • Decipher评分与Gleason GG独立相关,与PI-RADSv2评分无关。

核心结论

  • Decipher活检基因组检测与Gleason GG相关,独立于PI-RADSv2评分。
  • 高风险基因组分类可见于所有PI-RADS类别与GG1/GG2组合,提示Decipher检测在低- favorable中危前列腺癌中有潜在 utility。
  • 对于接受主动监测的患者,确认性基因组检测似乎比PI-RADSv2评分更有价值。

研究设计与样本

  • 对Gleason GG1和GG2的男性行MRI-超声靶向穿刺(感兴趣区)及同期12针系统穿刺。
  • 亚组分析评估接受根治性前列腺切除术(RP)的患者及靶向穿刺核心Decipher检测的男性。

主要发现

  • 3个mpMRI类别间中位Decipher评分无显著差异。

临床怎么用

  • 在低至 favorable中危前列腺癌患者中,可考虑使用Decipher活检基因组检测辅助风险评估。
  • 对于主动监测患者,Decipher检测可能比PI-RADSv2评分提供更多独立于影像的预后信息。
  • PI-RADS评分与Gleason GG组合评估时,应意识到高风险基因组分类可出现在所有组合中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the association between Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) score, the Decipher score, and histologic grade of carcinoma in biopsy tissue among low- to intermediate-risk prostate cancer patients. METHODS: MRI-ultrasound targeted biopsy of regions of interest and concurrent 12-core systematic biopsy was performed on men with Gleason grade group (GG) 1 and 2. We compared Decipher score with PI-RADS scores and biopsy Gleason GG. Subgroup analyses were performed to evaluate patients who underwent radical prostatectomy (RP), and men with Decipher testing from a targeted biopsy core. RESULTS: One hundred two patients with GG1 and GG2 had biopsy Decipher testing. There was no significant difference in the median Decipher scores among the 3 multiparametric magnetic resonance imaging categories. Patients with GG2 vs GG1 in the setting of PI-RADS 4-5 had higher genomic scores (P = .01), but no significant difference was noted in patients with PI-RADS ≤3. The rate of genomic higher-risk disease on a targeted biopsy from PI-RADS5 was higher in GG2 (75%) vs GG1 (11.1%; P = .01). On multivariable logistic regression analysis, the Decipher score ≥0.45, (odds ratio (OR) 2.71; P = .02), and age (OR 1.11; P = .004) remained significant factors associated with Gleason GG2 on biopsy. CONCLUSION: High-risk genomic classification can be seen across all combinations of PI-RADS categories and Gleason GG1 and GG2, confirming a potential utility for Decipher testing in men with low- to favorable intermediate-risk prostate cancer. The Decipher biopsy genomic test related to Gleason GG independent of PI-RADSv2 score. Confirmatory genomic testing for patients undergoing active surveillance appears more valuable than PI-RADSv2 score.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Martin DT, Ghabili K, Levi A, et al. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies. Urology. 2018. PMID: 30552940. doi:10.1016/j.urology.2018.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。